Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more
Bicycle Therapeutics plc (50BA) - Total Assets
Latest total assets as of September 2025: €763.95 Million EUR
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) holds total assets worth €763.95 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bicycle Therapeutics plc - Total Assets Trend (2018–2024)
This chart illustrates how Bicycle Therapeutics plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bicycle Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Bicycle Therapeutics plc's total assets of €763.95 Million consist of 97.1% current assets and 3.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 91.9% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Bicycle Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bicycle Therapeutics plc's current assets represent 97.1% of total assets in 2024, an increase from 94.1% in 2018.
- Cash Position: Cash and equivalents constituted 91.9% of total assets in 2024, up from 77.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bicycle Therapeutics plc Competitors by Total Assets
Key competitors of Bicycle Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Bicycle Therapeutics plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bicycle Therapeutics plc generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bicycle Therapeutics plc is currently not profitable relative to its asset base.
Bicycle Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.66 | 17.13 | 9.36 |
| Quick Ratio | 10.66 | 17.13 | 9.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €669.54 Million | € 909.79 Million | € 194.51 Million |
Bicycle Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Bicycle Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 60.7% |
| Total Assets | €956.87 Million |
| Market Capitalization | $8.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bicycle Therapeutics plc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bicycle Therapeutics plc's assets grew by 60.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bicycle Therapeutics plc (2018–2024)
The table below shows the annual total assets of Bicycle Therapeutics plc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €956.87 Million | +60.73% |
| 2023-12-31 | €595.34 Million | +44.99% |
| 2022-12-31 | €410.61 Million | -14.42% |
| 2021-12-31 | €479.79 Million | +197.73% |
| 2020-12-31 | €161.15 Million | +46.24% |
| 2019-12-31 | €110.19 Million | +35.00% |
| 2018-12-31 | €81.63 Million | -- |